LungLife AI, Inc.
LLAI.L · LSE
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.09 | 0.10 | -0.05 | -0.80 |
| FCF Yield | -34.15% | -22.65% | -23.25% | -4.04% |
| EV / EBITDA | -2.45 | -3.26 | -3.97 | -16.16 |
| Quality | ||||
| ROIC | -67.87% | -55.41% | -25.52% | -15.61% |
| Gross Margin | 100.00% | 100.00% | 50.77% | 8.29% |
| Cash Conversion Ratio | 0.93 | 0.77 | 1.01 | 0.59 |
| Growth | ||||
| Revenue 3-Year CAGR | -38.27% | -51.09% | 12.74% | -40.66% |
| Free Cash Flow Growth | 14.05% | 36.82% | -225.98% | 15.66% |
| Safety | ||||
| Net Debt / EBITDA | 0.47 | 0.34 | 2.07 | 2.71 |
| Interest Coverage | -137.37 | -146.88 | -12.82 | -5.23 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 2,357.29 | -803.79 | -1,524.60 |